莫西沙星超短程治疗初治103例菌阳肺结核的临床效果

黄玲 刘国辉

摘 要 目的：探讨对初治菌阳肺结核患者应用莫西沙星超短程治疗的临床效果。方法：选取206例初治菌阳肺结核患者，用随机数字表法分为对照组（n=103）和观察组（n=103）。对照组给予常规治疗，观察组在此基础上联合莫西沙星超短程治疗。对比两组病灶吸收有效率和不良反应发生情况；对比治疗2个月和疗程结束时两组痰结核菌转阴率。结果：治疗后观察组病灶吸收有效率显著优于对照组（98.0% vs 86.4%）；治疗2个月和疗程结束时痰结核菌转阴率均优于对照组；不良反应发生率显著低于对照组（3.9% vs 13.6%）（均P<0.05）。结论：莫西沙星超短程治疗能有效提高初治菌阳肺结核患者病灶吸收有效率和痰结核菌转阴率，不良反应少，疗效显著。

关键词 莫西沙星 超短程治疗 菌阳肺结核 临床效果

中图分类号：R978.19； R521 文献标志码：A 文章编号：1006-1533（2021）17-0022-02

Clinical efficacy of ultra-short course moxifloxacin in the treatment of 103 cases of bacteriological positive pulmonary tuberculosis

HUANG Ling， LIU Guohui

（Department of Pulmonary， the Third Peoples Hospital of Shenzhen， Shenzhen 518000， China）

ABSTRACT Objective： To investigate the clinical effect of ultra-short course moxifloxacin in the treatment of patients with newly diagnosed bacteriological positive pulmonary tuberculosis. Methods： Two hundred and six patients with bacteriological positive pulmonary tuberculosis were randomly divided into a control group （n=103） and an observation group（n=103）. The control group was treated with routine therapy， and the observation group was additionally given ultra-short course moxifloxacin on this basis. The absorption rate and adverse reactions were compared between the two groups. The negative rates of sputum tuberculosis at 2 months after treatment and the end of treatment were also compared between the two groups. Results： After treatment， the effective rates of lesion absorption were significantly higher in the observation group than the control group（98.0% vs 86.4%）. The negative rates of sputum tuberculosis were better and the incidence of adverse reactions was significantly lower in the observation group than the control group （all P<0.05）. Conclusion： Ultra-short course moxifloxacin treatment can effectively improve the absorption rates of the lesion and the negative rates of sputum tuberculosis with less adverse reactions and significant efficacy.

KEy WORDS moxifloxacin； ultra-short course treatment； bacteriological positive pulmonary tuberculosis； clinical efficacy

肺結核属于呼吸道慢性传染性疾病，由结核分枝杆菌引起，会损伤人体多个脏器。分枝杆菌感染后，人体抵抗力和免疫力会下降，最终诱发肺结核。早期诊断治疗对该疾病效果较好，患者治愈几率较大。初治菌阳肺结核患者通常指未使用过抗结核药物或使用时间不超过1个月，且痰培养和涂片检查呈阳性的肺结核患者。临床通常采用短程、早期和联合治疗原则[1]。莫西沙星属于新型抗菌药物，抗菌性强，效果显著，因此常用于初治菌阳肺结核患者临床治疗。本文以206例初治菌阳肺结核患者为研究对象，分析莫西沙星超短程治疗效果，现报道如下。

1 临床资料与方法

1.1 临床资料

选取我院2018年2月—2020年1月收治的206例初治菌阳肺结核患者为研究对象，采取随机数字表法机分为观察组和对照组各103例。……